These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27199349)

  • 1. miR-29b Mediates NF-κB Signaling in KRAS-Induced Non-Small Cell Lung Cancers.
    Langsch S; Baumgartner U; Haemmig S; Schlup C; Schäfer SC; Berezowska S; Rieger G; Dorn P; Tschan MP; Vassella E
    Cancer Res; 2016 Jul; 76(14):4160-9. PubMed ID: 27199349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in
    Inoue A; Mizushima T; Wu X; Okuzaki D; Kambara N; Ishikawa S; Wang J; Qian Y; Hirose H; Yokoyama Y; Ikeshima R; Hiraki M; Miyoshi N; Takahashi H; Haraguchi N; Hata T; Matsuda C; Doki Y; Mori M; Yamamoto H
    Mol Cancer Ther; 2018 May; 17(5):977-987. PubMed ID: 29545333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in
    Mehta AK; Hua K; Whipple W; Nguyen MT; Liu CT; Haybaeck J; Weidhaas J; Settleman J; Singh A
    Sci Signal; 2017 Sep; 10(496):. PubMed ID: 28900044
    [No Abstract]   [Full Text] [Related]  

  • 4. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
    Gasparini P; Cascione L; Landi L; Carasi S; Lovat F; Tibaldi C; Alì G; D'Incecco A; Minuti G; Chella A; Fontanini G; Fassan M; Cappuzzo F; Croce CM
    Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14924-9. PubMed ID: 26627242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NF-κB-Induced Upregulation of miR-548as-3p Increases Invasion of NSCLC by Targeting PTEN.
    Akgun S; Kucuksayan H; Ozes ON; Can O; Alikanoglu AS; Yildiz M; Akca H
    Anticancer Agents Med Chem; 2019; 19(8):1058-1068. PubMed ID: 30727918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.
    Zhou Y; Dang J; Chang KY; Yau E; Aza-Blanc P; Moscat J; Rana TM
    Cancer Res; 2016 Oct; 76(19):5777-5787. PubMed ID: 27698189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.
    McNew KL; Whipple WJ; Mehta AK; Grant TJ; Ray L; Kenny C; Singh A
    Mol Cancer Res; 2016 Dec; 14(12):1204-1216. PubMed ID: 27655129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
    Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
    Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Ras in metal-induced EGF receptor signaling and NF-kappaB activation in human airway epithelial cells.
    Wu W; Jaspers I; Zhang W; Graves LM; Samet JM
    Am J Physiol Lung Cell Mol Physiol; 2002 May; 282(5):L1040-8. PubMed ID: 11943669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
    Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
    Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
    Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
    Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-449a Suppresses Tumor Growth, Migration, and Invasion in Non-Small Cell Lung Cancer by Targeting a HMGB1-Mediated NF-κB Signaling Pathway.
    Wu D; Liu J; Chen J; He H; Ma H; Lv X
    Oncol Res; 2019 Feb; 27(2):227-235. PubMed ID: 29562957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the KRAS, p38α, and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor.
    Zarredar H; Pashapour S; Farajnia S; Ansarin K; Baradaran B; Ahmadzadeh V; Safari F
    J Cell Biochem; 2019 Jun; 120(6):10670-10677. PubMed ID: 30656741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
    Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.